GlobeNewswire·Oct 9, 2026, 4:05 PM ET

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte, Inc. closed concurrent public offerings comprising 8,584,375 shares of common stock, 400,000 pre-funded warrants, and $575 million in 1.50% convertible senior notes due 2032.
The offerings included the full exercise of underwriter options for 1,171,875 additional common stock shares and an additional $75 million in convertible notes to cover over-allotments.
Aggregate gross proceeds from the offerings totaled approximately $1.15 billion before deducting underwriting discounts, commissions, and offering expenses.
Net proceeds will fund clinical development of VAX-31 adult & pediatric programs, including OPUS-2, OPUS-3, & an infant Phase 2 dose-finding study.
Funds will also support manufacturing scale-up, inventory building, & commercial preparations for the anticipated U.S. launch of VAX-31 in adults.
Additional capital will be allocated to early-stage pipeline research, general corporate purposes, working capital, & potential pipeline expansion.
Joint book-running managers for the common stock & warrant offering included Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Goldman Sachs, & Guggenheim Securities.
Jefferies, Leerink Partners, BofA Securities, Goldman Sachs, & Evercore ISI served as joint book-running managers for the note offering.
Vaxcyte's pipeline features VAX-31 (31-valent PCV), VAX-24 (24-valent PCV), VAX-XL, VAX-A1 (Group A Strep), & VAX-GI (Shigella).